Penumbra, Inc. (PEN)
NYSE: PEN · IEX Real-Time Price · USD
199.19
-2.85 (-1.41%)
Apr 30, 2024, 1:28 PM EDT - Market open
Penumbra Revenue
In the year 2023, Penumbra had annual revenue of $1.06B with 24.95% growth. Revenue in the quarter ending December 31, 2023 was $284.68M with 28.69% year-over-year growth.
Revenue (ttm)
$1.06B
Revenue Growth
+24.95%
P/S Ratio
7.29
Revenue / Employee
$252,029
Employees
4,200
Market Cap
7.70B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.06B | 211.39M | 24.95% |
Dec 31, 2022 | 847.13M | 99.54M | 13.32% |
Dec 31, 2021 | 747.59M | 187.18M | 33.40% |
Dec 31, 2020 | 560.41M | 13.01M | 2.38% |
Dec 31, 2019 | 547.41M | 102.47M | 23.03% |
Dec 31, 2018 | 444.94M | 111.17M | 33.31% |
Dec 31, 2017 | 333.76M | 70.45M | 26.75% |
Dec 31, 2016 | 263.32M | 77.22M | 41.50% |
Dec 31, 2015 | 186.10M | 60.59M | 48.27% |
Dec 31, 2014 | 125.51M | 36.66M | 41.26% |
Dec 31, 2013 | 88.85M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bio-Rad Laboratories | 2.67B |
Masimo | 2.05B |
Exelixis | 1.83B |
Inspire Medical Systems | 624.80M |
Intra-Cellular Therapies | 464.37M |
Ascendis Pharma | 296.35M |
Legend Biotech | 285.14M |
PEN News
- 7 days ago - Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots - PRNewsWire
- 20 days ago - Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024 - PRNewsWire
- 2 months ago - Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results - PRNewsWire
- 3 months ago - Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024 - PRNewsWire
- 4 months ago - Penumbra, Inc. to Present at the J.P. Morgan 42nd Annual Healthcare Conference - PRNewsWire
- 5 months ago - First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary Embolism - PRNewsWire
- 5 months ago - Penumbra, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference - PRNewsWire
- 6 months ago - Penumbra Teams Up with Honor Everywhere to Bring US War Memorials to Aging Veterans - PRNewsWire